StockData

ClearPoint Neuro vs TriSalus Life Sciences

CLPT and TLSI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CLPT and TLSI compare

ClearPoint Neuro is the larger company, worth 1.8 times as much as TriSalus Life Sciences ($252M against $141M).

ClearPoint Neuro grew revenue faster over the last twelve months (32.5% versus 25.2% for TriSalus Life Sciences).

TriSalus Life Sciences keeps more of each dollar of sales as profit, with a net margin of −62.6% compared with −79.4% at ClearPoint Neuro.

TriSalus Life Sciences scores higher on the StockData Score (5 against 4 for ClearPoint Neuro), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCLPTTLSI
Size and price
Market cap$252M$141M
Share price$7.86$2.29
Change, 1 year−49.1%−49.7%
Change, 5 years−43.2%−77.0%
Beta (5Y)2.692.29
Employees172102
StockData Score
Total score45 (better)
Valuation score00
Growth score33
Performance score01 (better)
Health score11
Dividend score00
Valuation
P/S5.5×3.1× (better)
P/B9.2× (better)21.6×
FCF yield−19.1%−16.5% (better)
Fair value$7.04–
Margin of safety−11.6%–
Growth
Revenue growth (TTM)32.5% (better)25.2%
Revenue growth, 5Y average23.6%–
Profitability
Gross margin61.4%85.8% (better)
Operating margin−70.6%−67.7% (better)
Net margin−79.4%−62.6% (better)
FCF margin−106%−51.6% (better)
Return on equity−168%–
Return on invested capital−131%–
Financial health
Debt / equity1.86 (better)5.05
Interest coverage−6.0×−5.2× (better)
Current ratio6.76 (better)5.35
Altman Z-score−1.21 (better)−6.02
Piotroski F-score5 (better)3
Dividends and buybacks
Buyback yield–−31.3%
Shareholder yield0.00% (better)−31.3%
Ownership
Held by institutions43.4%38.6%
Held by insiders3.6%29.7%
Insider net buying, 12 months−$2.5M$3.6M (better)
Short interest, % of float13.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.